Fiche du document
- doi: 10.1016/j.gastrohep.2019.09.010
- issn: 0210-5705
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.gastrohep.2019.09.010
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/31810796
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0210-5705
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_F6B0092FDA460
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Immune globulins Antibodies Immune serum globulinCiter ce document
J. Vionnet et al., « Donor-specific antibodies in liver transplantation. », Serveur académique Lausannois, ID : 10.1016/j.gastrohep.2019.09.010
Métriques
Partage / Export
Résumé
Despite unique immunoregulatory properties pointing toward tolerance, the liver allograft can be negatively impacted by humoral alloreactivity, with immediate as well as long-term harmful consequences. With regard to the unmet need of long-term outcomes improvement after liver transplantation, donor-specific antibodies have recently been the matter of intense study in this context. We review here recent advances regarding the understanding of the impact of preformed as well as de novo anti-human leukocyte antigen donor-specific antibodies in liver transplantation and discuss potential strategies to overcome this problem.